Courier Therapeutics Inc

Biotech · Acquired

IL-2 fusion protein that selectively activates cytotoxic T lymphocytes for cancer immunotherapy

couriertherapeutics.com →
Grants
$576K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Novel Immuno-oncology Strategy for Targeted Cytotoxic Lymphocyte Activation$288,105
Federal grantDepartment of Health and Human Services · Phase I · Novel Immuno-oncology Strategy for Targeted Cytotoxic Lymphocyte Activation$288,105
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2067Bespoke, Inc.—$14M
2068D BioTherapeutics, LLC——
2069Isomorphic Labs——
2070Courier Therapeutics Inc——
2071UNLOCKED LABS INC.——
2072Slingshot Biosciences—$24M
2073ANI Energy, LLC—$1.5M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 2
  • Orthopoxvirus Major Histocompatibility Complex (mhc) Class-i Like Protein (omcp) For Treatment Of Autoimmune Diseaseapplication
  • BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS l-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNERapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.